Syngene International confirms expansion of biologics facility to provide fully integrated end-to-end services for antibody-drug conjugates (ADCs) from discovery through GMP manufacturing.
Impact
Low
Severity
Low
Justification
Routine business expansion in ordinary course, not material under SEBI criteria. No immediate compliance actions required.
Syngene International provides clarification on news article regarding expansion of biologics facility to offer integrated antibody-drug conjugate (ADC) services from discovery through GMP manufacturing.
Impact
Low
Severity
Low
Justification
Routine disclosure clarifying news article about non-material business expansion in ordinary course of business; does not meet materiality criteria under SEBI Listing Regulations
BSE demat auction settlement listing securities and quantities for auction on October 13, 2025.
Impact
Medium
Severity
Medium
Justification
Routine demat auction settlement affecting multiple securities with specific quantities requiring delivery; impacts brokers and clients with short positions in listed securities.
BSE announces demat auction for settlement number 733 covering 91 scrips with specified quantities for auction on October 13, 2025.
Impact
Medium
Severity
Medium
Justification
Routine demat auction settlement affecting 91 securities. Important for brokers and investors with delivery obligations but represents standard market operations rather than systemic risk.